CA1049406A - Isolation of hemagglutinin and neuraminidase from influenza virus - Google Patents
Isolation of hemagglutinin and neuraminidase from influenza virusInfo
- Publication number
- CA1049406A CA1049406A CA217,790A CA217790A CA1049406A CA 1049406 A CA1049406 A CA 1049406A CA 217790 A CA217790 A CA 217790A CA 1049406 A CA1049406 A CA 1049406A
- Authority
- CA
- Canada
- Prior art keywords
- chloride
- bromide
- virus
- cationic detergent
- components
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 241000712461 unidentified influenza virus Species 0.000 title claims abstract description 16
- 101710154606 Hemagglutinin Proteins 0.000 title claims abstract description 13
- 102000005348 Neuraminidase Human genes 0.000 title claims abstract description 13
- 108010006232 Neuraminidase Proteins 0.000 title claims abstract description 13
- 101710093908 Outer capsid protein VP4 Proteins 0.000 title claims abstract description 13
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 title claims abstract description 13
- 101710176177 Protein A56 Proteins 0.000 title claims abstract description 13
- 239000000185 hemagglutinin Substances 0.000 title claims abstract description 13
- 238000002955 isolation Methods 0.000 title description 2
- 239000003599 detergent Substances 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 22
- 125000002091 cationic group Chemical group 0.000 claims abstract description 18
- 239000002245 particle Substances 0.000 claims abstract description 10
- 239000012736 aqueous medium Substances 0.000 claims abstract description 3
- 241000700605 Viruses Species 0.000 claims description 21
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 206010022000 influenza Diseases 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 238000005215 recombination Methods 0.000 claims description 6
- 230000006798 recombination Effects 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 5
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical group [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- KMVDECFGXJKYHV-UHFFFAOYSA-L trimethyl-[10-(trimethylazaniumyl)decyl]azanium;dichloride Chemical compound [Cl-].[Cl-].C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C KMVDECFGXJKYHV-UHFFFAOYSA-L 0.000 claims description 3
- QWZLBLDNRUUYQI-UHFFFAOYSA-M Methylbenzethonium chloride Chemical compound [Cl-].CC1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 QWZLBLDNRUUYQI-UHFFFAOYSA-M 0.000 claims description 2
- 150000001450 anions Chemical class 0.000 claims description 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 claims description 2
- 229960001950 benzethonium chloride Drugs 0.000 claims description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical group [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 2
- 229960002285 methylbenzethonium chloride Drugs 0.000 claims description 2
- 239000000306 component Substances 0.000 claims 3
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 claims 1
- 229960002233 benzalkonium bromide Drugs 0.000 claims 1
- 229960000686 benzalkonium chloride Drugs 0.000 claims 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims 1
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 claims 1
- CEYYIKYYFSTQRU-UHFFFAOYSA-M trimethyl(tetradecyl)azanium;chloride Chemical group [Cl-].CCCCCCCCCCCCCC[N+](C)(C)C CEYYIKYYFSTQRU-UHFFFAOYSA-M 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 abstract description 11
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
- 229930006000 Sucrose Natural products 0.000 description 7
- 239000005720 sucrose Substances 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 229960003971 influenza vaccine Drugs 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 229940031626 subunit vaccine Drugs 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- NEUSVAOJNUQRTM-UHFFFAOYSA-N cetylpyridinium Chemical class CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NEUSVAOJNUQRTM-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229960004279 formaldehyde Drugs 0.000 description 2
- 235000019256 formaldehyde Nutrition 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 210000000605 viral structure Anatomy 0.000 description 2
- UPCOSYBELNEQAU-UHFFFAOYSA-L (2-decoxy-2-oxoethyl)-[2-[(2-decoxy-2-oxoethyl)-dimethylazaniumyl]ethyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCOC(=O)C[N+](C)(C)CC[N+](C)(C)CC(=O)OCCCCCCCCCC UPCOSYBELNEQAU-UHFFFAOYSA-L 0.000 description 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 101100058513 Caenorhabditis elegans glo-2 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000237074 Centris Species 0.000 description 1
- CXRFDZFCGOPDTD-UHFFFAOYSA-M Cetrimide Chemical compound [Br-].CCCCCCCCCCCCCC[N+](C)(C)C CXRFDZFCGOPDTD-UHFFFAOYSA-M 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000726306 Irus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 241000831652 Salinivibrio sharmensis Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229940001007 aluminium phosphate Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229960003872 benzethonium Drugs 0.000 description 1
- VZWMKHUMEIECPK-UHFFFAOYSA-M benzyl-dimethyl-octadecylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 VZWMKHUMEIECPK-UHFFFAOYSA-M 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229960004830 cetylpyridinium Drugs 0.000 description 1
- RLGQACBPNDBWTB-UHFFFAOYSA-N cetyltrimethylammonium ion Chemical class CCCCCCCCCCCCCCCC[N+](C)(C)C RLGQACBPNDBWTB-UHFFFAOYSA-N 0.000 description 1
- -1 chlor- Chemical class 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- SIYLLGKDQZGJHK-UHFFFAOYSA-N dimethyl-(phenylmethyl)-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethyl]ammonium Chemical compound C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 SIYLLGKDQZGJHK-UHFFFAOYSA-N 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 229940102728 methylbenzethonium Drugs 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- NQLVQOSNDJXLKG-UHFFFAOYSA-N prosulfocarb Chemical compound CCCN(CCC)C(=O)SCC1=CC=CC=C1 NQLVQOSNDJXLKG-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- GLFDLEXFOHUASB-UHFFFAOYSA-N trimethyl(tetradecyl)azanium Chemical compound CCCCCCCCCCCCCC[N+](C)(C)C GLFDLEXFOHUASB-UHFFFAOYSA-N 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Detergent Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH44774A CH589453A5 (no) | 1974-01-14 | 1974-01-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1049406A true CA1049406A (en) | 1979-02-27 |
Family
ID=4187233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA217,790A Expired CA1049406A (en) | 1974-01-14 | 1975-01-13 | Isolation of hemagglutinin and neuraminidase from influenza virus |
Country Status (27)
| Country | Link |
|---|---|
| JP (2) | JPS58407B2 (no) |
| AT (1) | AT345449B (no) |
| AU (1) | AU500250B2 (no) |
| BE (1) | BE824372A (no) |
| CA (1) | CA1049406A (no) |
| CH (1) | CH589453A5 (no) |
| CS (1) | CS191254B2 (no) |
| DD (1) | DD116239A5 (no) |
| DE (1) | DE2500785B2 (no) |
| DK (1) | DK140003B (no) |
| ES (1) | ES433759A1 (no) |
| FI (1) | FI54053C (no) |
| FR (1) | FR2257305B1 (no) |
| GB (1) | GB1498261A (no) |
| HK (1) | HK56380A (no) |
| HU (1) | HU173920B (no) |
| IE (1) | IE40794B1 (no) |
| IL (1) | IL46426A (no) |
| MY (1) | MY8100204A (no) |
| NL (1) | NL166622C (no) |
| NO (1) | NO143128C (no) |
| PH (1) | PH14458A (no) |
| PL (1) | PL93689B1 (no) |
| SE (1) | SE427238B (no) |
| SU (1) | SU616997A3 (no) |
| YU (1) | YU41289B (no) |
| ZA (1) | ZA75259B (no) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2829089A1 (de) * | 1977-07-13 | 1979-02-01 | Sandoz Ag | Subunit-vakzine |
| JPH0688911B2 (ja) * | 1985-06-06 | 1994-11-09 | 国立予防衛生研究所長 | インフルエンザワクチン及びその製造方法 |
| TW570803B (en) * | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
| EP0919243A1 (en) | 1997-11-25 | 1999-06-02 | Duphar International Research B.V | Vaccine containing B subunits of heat-labile enterotoxin (LTB) of Escherichia coli as an adjuvant |
| DE19938767C2 (de) * | 1999-08-16 | 2002-10-24 | Tad Pharma Gmbh | Spaltimpfstoffe |
| AU2006310171B2 (en) * | 2005-11-01 | 2011-02-17 | Seqirus UK Limited | Cell-derived viral vaccines with low levels of residual cell DNA by beta-propiolactone treatment |
| RU2496519C2 (ru) | 2007-08-28 | 2013-10-27 | Бакстер Интернэшнл Инк. | Способ получения препарата, содержащего вирусные антигены, и применение препарата |
| JP6373376B2 (ja) | 2013-11-15 | 2018-08-15 | ノバルティス アーゲー | 残留細胞培養不純物の除去 |
-
1974
- 1974-01-14 CH CH44774A patent/CH589453A5/xx not_active IP Right Cessation
-
1975
- 1975-01-06 NO NO750031A patent/NO143128C/no unknown
- 1975-01-06 FI FI750014A patent/FI54053C/fi not_active IP Right Cessation
- 1975-01-06 DK DK1475AA patent/DK140003B/da not_active IP Right Cessation
- 1975-01-07 SE SE7500130A patent/SE427238B/xx not_active IP Right Cessation
- 1975-01-10 NL NL7500301.A patent/NL166622C/xx not_active IP Right Cessation
- 1975-01-10 DE DE2500785A patent/DE2500785B2/de active Granted
- 1975-01-13 DD DD183614A patent/DD116239A5/xx unknown
- 1975-01-13 AT AT21475A patent/AT345449B/de not_active IP Right Cessation
- 1975-01-13 GB GB1290/75A patent/GB1498261A/en not_active Expired
- 1975-01-13 HU HU75SA2736A patent/HU173920B/hu not_active IP Right Cessation
- 1975-01-13 PH PH16702A patent/PH14458A/en unknown
- 1975-01-13 IL IL46426A patent/IL46426A/xx unknown
- 1975-01-13 PL PL1975177303A patent/PL93689B1/pl unknown
- 1975-01-13 CA CA217,790A patent/CA1049406A/en not_active Expired
- 1975-01-13 ES ES433759A patent/ES433759A1/es not_active Expired
- 1975-01-13 IE IE59/75A patent/IE40794B1/xx unknown
- 1975-01-13 YU YU58/75A patent/YU41289B/xx unknown
- 1975-01-14 CS CS75255A patent/CS191254B2/cs unknown
- 1975-01-14 BE BE152368A patent/BE824372A/xx not_active IP Right Cessation
- 1975-01-14 AU AU77305/75A patent/AU500250B2/en not_active Expired
- 1975-01-14 JP JP50006975A patent/JPS58407B2/ja not_active Expired
- 1975-01-14 ZA ZA00750259A patent/ZA75259B/xx unknown
- 1975-01-14 FR FR7501007A patent/FR2257305B1/fr not_active Expired
- 1975-01-14 SU SU752101722A patent/SU616997A3/ru active
-
1980
- 1980-10-09 HK HK563/80A patent/HK56380A/xx unknown
-
1981
- 1981-01-29 JP JP56012831A patent/JPS6035326B2/ja not_active Expired
- 1981-12-30 MY MY204/81A patent/MY8100204A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Collisson et al. | Cytotoxic T lymphocytes are critical in the control of infectious bronchitis virus in poultry | |
| Kilbourne | Comparative efficacy of neuraminidase-specific and conventional influenza virus vaccines in induction of antibody to neuraminidase in humans | |
| Leist et al. | Virus-triggered immune suppression in mice caused by virus-specific cytotoxic T cells. | |
| US4064232A (en) | Process for isolating the immunogenic components of influenza viruses | |
| CA1049406A (en) | Isolation of hemagglutinin and neuraminidase from influenza virus | |
| US4140762A (en) | Influenza sub-unit vaccine | |
| Rytel et al. | The Influence of Cortisone on Experimental Viral Infection: VIII. Suppression by Cortisone of Interferon Formation in Mice Injected With Newcastle Disease Virus | |
| AU2022209359A1 (en) | Multivalent feline vaccine | |
| WO2019110213A1 (en) | Feline calicivirus vaccine | |
| JPH10508485A (ja) | 弱毒化イヌパルボウイルス | |
| McLaren et al. | Defective interfering particles from poliovirus vaccine and vaccine reference strains | |
| Alexandrova et al. | Laboratory properties of cold-adapted influenza B live vaccine strains developed in the US and USSR, and their B/Ann Arbor/1/86 cold-adapted reassortant vaccine candidates | |
| US3892627A (en) | Feline panleukopenia vaccine | |
| CN103228293A (zh) | 用于在哺乳动物中预防和治疗金迪普拉病毒感染的疫苗制剂 | |
| DE2829089A1 (de) | Subunit-vakzine | |
| CA1292690C (en) | Vaccine comprising an immunogenic protein and, as an adjuvant, a substantially non-immunogenic sequentially homologous peptide | |
| Kilbourne et al. | Hemagglutinin mutants of swine influenza virus differing in replication characteristics in their natural host | |
| US11229699B2 (en) | Feline calicivirus vaccine | |
| Iwasaki et al. | Communications: Effect of Lymphocytosis-Promoting Factor (LPF) on the Appearance of Antibodies in Mice Infected with Influenza Virus | |
| CA1270438A (en) | Influenza vaccine | |
| KR790001144B1 (ko) | 인플루엔자 백신의 제조방법 | |
| EP3706789A1 (en) | Feline calicivirus vaccine | |
| CA2112225C (en) | Attenuated revertant serotype 1 marek's disease vaccine | |
| Lomniczi | Properties of non-neurovirulent plaque-forming mutants of Newcastle disease virus | |
| Brown | Foot-and-mouth disease virus |